’19 NOVEL P62 LIGAND COMPOUND, AND COMPOSITION FOR PREVENTING, ALLEVIATING, OR TREATING PROTEINOPATHIES COMPRISING SAME 2nd (KR, US, EP, JP, CN, TW)
The present invention relates to a novel p62 ligand compound, or a stereoisomer, solvate, hydrate, or prodrug thereof, and a pharmaceutical or food composition for preventing or treating proteopathies comprising same as an active ingredient.
The p62 ligand compound according to the present invention activates selective autophagy in cells, thereby selectively removes proteins, organelles, and aggregates in the body, and thus can be usefully employed as a pharmaceutical composition for preventing, alleviating, or treating various proteinopathies.
- '19 NOVEL COMPOUND AND PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING OBESITY OR METABOLIC SYNDROME COMPRISING SAME 1st(KR, US, EP, JP, CN, TW)
- ’19 NOVEL AUTOPHAGY-TARGETING CHIMERA (AUTOTAC) COMPOUND, AND COMPOSITION FOR PREVENTING, ALLEVIATING, OR TREATING DISEASES THROUGH TARGET PROTEIN DEGRADATION COMPRISING SAME (KR, US, EP, JP, CN, AU,